|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 56.32 USD | +1.77% |
|
+4.65% | +45.91% |
| Capitalization | 3.49B 3.02B 2.84B 2.57B 4.75B 299B 5.35B 32.99B 12.88B 137B 13.1B 12.82B 502B | P/E ratio 2025 * |
-32x | P/E ratio 2026 * | -225x |
|---|---|---|---|---|---|
| Enterprise value | 3.37B 2.92B 2.74B 2.48B 4.59B 289B 5.17B 31.89B 12.45B 133B 12.66B 12.39B 485B | EV / Sales 2025 * |
41.2x | EV / Sales 2026 * | 17.1x |
| Free-Float |
95.31% | Yield 2025 * |
-
| Yield 2026 * | - |
More valuation ratios
* Estimated data
More news
Last Transcript: Protagonist Therapeutics, Inc.
More recommendations
More press releases
| 1 day | +1.77% | ||
| 1 week | +4.65% | ||
| Current month | +18.64% | ||
| 1 month | +24.41% | ||
| 3 months | -2.31% | ||
| 6 months | +39.47% | ||
| Current year | +45.91% |
| 1 week | 54.1 |  | 57.7 |
| 1 month | 43.2 | | 57.7 |
| Current year | 33.7 | | 60.6 |
| 1 year | 30.67 | | 60.6 |
| 3 years | 6.91 | | 60.6 |
| 5 years | 6.91 | | 60.6 |
| 10 years | 4.47 | | 60.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
CEO | Chief Executive Officer | 68 | 2008-11-30 |
Asif Ali
DFI | Director of Finance/CFO | 51 | 2022-04-17 |
Newman Yeilding
CTO | Chief Tech/Sci/R&D Officer | - | 2025-01-01 |
| Director | Title | Age | Since |
|---|---|---|---|
Dinesh Patel
BRD | Director/Board Member | 68 | 2008-11-30 |
Harold Selick
CHM | Chairman | 70 | 2014-03-18 |
William Waddill
BRD | Director/Board Member | 68 | 2016-06-30 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.77% | +4.65% | +65.79% | +668.35% | 3.49B | ||
| -1.58% | +0.28% | +19.52% | +10.49% | 50.66B | ||
| +0.19% | +7.98% | -26.82% | -23.26% | 27.53B | ||
| +1.05% | +4.51% | -4.60% | +16.70% | 26.72B | ||
| -0.20% | +3.32% | +13.39% | -24.44% | 12.56B | ||
| +0.64% | +21.43% | - | - | 12.33B | ||
| +1.06% | +9.10% | -54.00% | -32.91% | 11.69B | ||
| -1.44% | +4.71% | -81.49% | -78.48% | 10.58B | ||
| -0.47% | -3.73% | +30.20% | +106.47% | 10.32B | ||
| +1.43% | +4.02% | +4.17% | -0.42% | 10.26B | ||
| Average | -0.64% | +6.26% | -3.76% | +71.39% | 17.61B | |
| Weighted average by Cap. | -0.86% | +5.97% | -3.74% | +13.69% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 81.92M 70.78M 66.63M 60.29M 112M 7.02B 126M 774M 302M 3.22B 307M 301M 11.77B | 189M 163M 153M 139M 257M 16.15B 289M 1.78B 696M 7.42B 707M 693M 27.1B |
| Net income | -112M -97.08M -91.4M -82.7M -153M -9.62B -172M -1.06B -415M -4.42B -422M -413M -16.15B | 26.77M 23.13M 21.77M 19.7M 36.45M 2.29B 41.05M 253M 98.77M 1.05B 100M 98.31M 3.85B |
| Net Debt | -117M -101M -94.91M -85.88M -159M -9.99B -179M -1.1B -431M -4.59B -438M -429M -16.77B | -264M -228M -214M -194M -359M -22.57B -404M -2.49B -972M -10.37B -989M -968M -37.88B |
More financial data
* Estimated data
Employees
124
Calendar
06-19
- Annual General Meeting
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-06-12 | 56.32 $ | +1.77% | 800,582 |
| 25-06-11 | 55.34 $ | -1.83% | 677,210 |
| 25-06-10 | 56.37 $ | +1.24% | 1,269,564 |
| 25-06-09 | 55.68 $ | +2.39% | 1,121,220 |
| 25-06-06 | 54.38 $ | +1.04% | 1,073,756 |
Delayed Quote Nasdaq, June 12, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
56.32USD
Average target price
68.70USD
Spread / Average Target
+21.98%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- PTGX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition